Barbara Manni¹*, Lucia Federzoni², Patrizia Zucchi¹ and Andrea Fabbo¹

¹Cognitive Disorders and Dementia Unit, Primary Care Department, Local Agency for Health (AUSL) of Modena, Italy
²School of Geriatrics, University of Modena and Reggio Emilia, Modena, Italy

*Corresponding Author: Barbara Manni, Cognitive Disorders and Dementia Unit, Primary Care Department, Local Agency for Health (AUSL) of Modena, Italy.

Received: April 15, 2021; Published: June 04, 2021

Abstract

Mild cognitive disorder (MCI) may precede the onset of cognitive decline. Neuroinflammation may have a leading role in early phase of many neurocognitive diseases and may represent a useful target to limit MCI progression. Palmitoylethanolamide is endowed with anti-inflammatory and neuroprotective activities. Its formulation containing luteolin (PEALut) has been found to improve memory impairments in experimental models and in cognitively impaired patients suggesting its potential use for delaying the dementia onset. This retrospective study provides a preliminary evaluation of PEALut effect on clinical aspects in MCI subjects. Data related to three MCI subject groups, matched case control for age, sex and comorbidity, were obtained via retrospective chart review. Groups received PEALut, dietary food and no treatment, respectively. Mini-Mental State Examination (MMSE) questionnaire was used to evaluate cognitive symptoms; Activity Daily Living and Instrumental Activity functional Daily Living were used for measuring activity daily living and functional status; UCLA-Neuropsychiatric Inventory was used for behavioral symptoms. All evaluations were performed at the baseline and after 6 months. PEALut group showed a significant improvement in short-term memory MMSE domain. Non cognitive behavioral disturbs were also improved in PEALut group. This latter effect seems to be limited to nonamnestic MCI patients. The data reported add another piece of the framework of evidence supporting the ability of PEA, or its composites, to slow down the progression of diseases of the central nervous system, and encourage to perform a double-blind clinical study to deepen PEALut effects on cognitive and non cognitive alterations.

Keywords: Dementia; Mild Cognitive Disorder; Neuropsychiatric Symptoms; PEALut

References

1. RC Petersen., et al. “Mild cognitive impairment: clinical characterization and outcome”. Archives of neurology3 (1999): 303-308.
2. A Bozoky., et al. “Mild cognitive impairments predict dementia in non demented elderly patients with memory loss”. Archives of neurology 58 (2001): 411-416.
3. RC Petersen. “Normal aging, mild cognitive impairment, and early Alzheimer’s disease”. Neurologist 1 (1995): 326-344.
4. SE Black. “Can SPECT predict the future for mild cognitive impairment?”. Canadian Journal of Neurological Sciences 26 (1999): 4-6.
5. K Ritchie and J Touchon. “Mild cognitive impairment: conceptual basis and current nosological status”. Lancet 355 (2000): 225-228.
6. PV Nunes., et al. “Neuropsychiatric Inventory in Community-Dwelling Older Adults with Mild Cognitive Impairment and Dementia”. Journal of Alzheimer’s Disease 2 (2019): 669-678.
7. M Grundman., et al. “Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials”. Archives of Neurology 1 (2004): 59-66.
8. PJ Ousset., et al. “Is Alzheimer's Disease Drug Development Broken? What Must Be Improved”. The Journal of Prevention of Alzheimer's Disease 1 (2014): 40-45.
9. D Kempuraj., et al. “Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis”. Frontiers in Neuroscience 11 (2017): 703.
10. KA Clayton., et al. “Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy”. Frontiers in Neuroscience 11 (2017): 680.
11. RE González-Reyes., et al. “Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective”. Frontiers in Molecular Neuroscience 10 (2017): 427.
12. NH Zawia., et al. “Epigenetics, oxidative stress, and Alzheimer disease”. Free Radical Biology and Medicine 46 (2009): 1241-1249.
13. E Esposito and S Cuzzocrea. “Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries”. CNS and Neurological Disorders - Drug Targets 1 (2013): 55-61.
14. G MattaceRaso., et al. “Palmitoylethanolamide in CNS health and disease”. Pharmacological Research 86 (2014): 32-41.
15. SD Skaper., et al. “N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution”. Molecular Neurobiology 2 (2015): 1034-1042.
16. G D'Agostino., et al. “Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease”. Neuropsychopharmacology 37 (2012): 1784-1792.
17. C Scuderi., et al. “Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects”. Translational Psychiatry1 (2018): 32.
18. R Crupi., et al. “Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression”. CNS and Neurological Disorders - Drug Targets 7 (2013): 989-1001.
19. R Liu., et al. “The anti-amnestic effects of Luteolin against amyloid-25-35 peptide-induced toxicity in mice involve the protection of neuromuscular unit”. Neuroscience 162 (2009): 1232-1243.
20. B Xu., et al. “Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats”. European Journal of Pharmacology1-3 (2010): 99-105.
21. RS Calabrò., et al. “PEALut efficacy in mild cognitive impairment: evidence from a SPECT case study!”. Aging Clinical and Experimental Research 6 (2016): 1279-1282.
22. C Caltagirone., et al. “Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man”. Translational Stroke Research1 (2016): 54-69.
23. NS Orefice., et al. “Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis”. Neurotherapeutics 2 (2016): 428-438.
24. V Uva. “Palmitoiletanolamide e Luteolina coultramicronizzate (co ultraPEALut) nel trattamento dei disturbi dell’umore nell’anziano”. Psicogeriatria 1 (2017): 79-87.
25. S Boccella., et al. “Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain”. International Journal of Molecular Sciences7 (2019).
26. MI Holubiec., et al. “Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia”. Psychopharmacology (Berl)10 (2018): 2929-2945.
27. RC Petersen., et al. “Mild cognitive impairment: a concept in evolution”. Journal of Internal Medicine 3 (2014): 214-228.
28. MA Sugarman., et al. “Neuropsychiatric symptoms and the diagnostic stability of Mild Cognitive Impairment”. Journal of Alzheimer's Disease 4 (2018): 1841-1855.
29. M Assogna., et al. “A possible role of palmitoylethanolamide combined with luteoline in frontotemporal dementia treatment: a clinical and neurophysiological study”. European Journal of Neurology 1 (2019): 112-346.
30. R Levi-Montalcini., et al. “Nerve growth factor: from neurotrophin to neurokine”. Trends in Neuroscience 19 (1996): 514-520.
31. L Aloe., et al. “A proposed autacoid mechanism controlling mastocyte behavior”. Agents Actions 39 (1993): 145-147.
32. SD Skaper., et al. “An Inflammation-Centric View of Neurological Disease: Beyond the Neuron”. Frontiers in Cellular Neuroscience 12 (2018): 72.
33. J Lo Verme., et al. “The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide”. Molecular Pharmacology 67 (2005): 15-19.
34. E Ryberg., et al. “The orphan receptor GPR55 is a novel cannabinoid receptor”. British Journal of Pharmacology 152 (2007): 1092-1101.
35. S Holmgren., et al. “Neuropsychiatric symptoms in dementia-a role for neuroinflammation?”. Brain Research Bulletin 108 (2014): 88-93.
36. S Brotini., et al. “Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease”. CNS and Neurological Disorders - Drug Targets6 (2017): 705-713.
37. E Palma., et al. “Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy”. Proceedings of the National Academy of Sciences 11 (2016): 3060-3065.
38. M Ghazizadeh-Hashemi., et al. “Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial”. Journal of Affective Disorders 232 (2018): 127-133.
39. M Khalaj., et al. “Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial”. Journal of Psychiatric Research 103 (2018): 104-111.
40. ML Lunardelli., et al. “Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations”. CNS and Neurological Disorders - Drug Targets7 (2019): 530-554.
41. Esempio J D., et al. “A structure for deoxyribose nucleic acid”. Nature 4356 (1953): 737-738.

Citation

Citation: Barbara Manni., et al. “Co-ultraPEALut Effect on Mild Cognitive Impairment: A Retrospective Observational Study”. Acta Scientific Neurology 4.7 (2021): 08-14.

Copyright

Copyright: © 2021 Barbara Manni., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.